You are here
VASADE BIOSCIENCES, INC.
UEI: J66DCHJSKWA4
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
A Novel Pharmacological Inhibitor of Adenylyl Cyclase Type 5 to Treat Alzheimer's Disease
Amount: $252,130.00Project Summary: Alzheimer’s Disease is associated with metabolic dysfunction, glucose and insulin resistance, oxidative stress, mitochondrial dysfunction, and reduced exercise capacity. Oxidative s ...
STTRPhase I2023Department of Health and Human Services National Institutes of Health -
Adenylyl Cyclase Type 5 Inhibition to Treat Myocardial Infarction
Amount: $1,388,427.00PROJECT SUMMARY/ABSTRACT The most significant advance in the treatment of Myocardial Infarction (MI) has been reperfusion therapy, which must be applied immediately after the MI diagnosis has been mad ...
SBIRPhase II2019Department of Health and Human Services National Institutes of Health -
Adenylyl Cyclase Type 5 Inhibition to Treat Myocardial Infarction
Amount: $172,153.00PROJECT SUMMARY ABSTRACT The most significant advance in the treatment of Myocardial InfarctionMIhas been reperfusion therapywhich must be applied immediately after the MI diagnosis has been madeDespi ...
SBIRPhase I2018Department of Health and Human Services National Institutes of Health -
AC5 inhibitor for heart failure
Amount: $1,620,985.00DESCRIPTION (provided by applicant): Cardiovascular disease is a critical health issue in the US and Western countries. The leading cause of death is heart failure (HF). Almost 5.5 million patients ar ...
SBIRPhase II2013Department of Health and Human Services National Institutes of Health -
Acute Coronary Syndrome animal model
Amount: $167,930.00DESCRIPTION (provided by applicant): Most new therapeutic measures that protect infarct size in experimental animals have failed in the clinics, to a large extent because they are only effective when ...
SBIRPhase I2012Department of Health and Human Services National Institutes of Health -
AC5 inhibitor for heart failure
Amount: $205,669.00DESCRIPTION (provided by applicant): Cardiovascular disease is a critical health issue in the US and Western countries. The leading cause of death is heart failure (HF). Almost 5.5 million patients ar ...
SBIRPhase I2012Department of Health and Human Services National Institutes of Health -
AntimiR-199a for cardiac ischemia and failure
Amount: $132,191.00DESCRIPTION (provided by applicant): Protecting the heart against ischemia or ischemia/reperfusion injury is one of the top health care objectives. Currently, one of the most effective mechanisms is ...
SBIRPhase I2010Department of Health and Human Services National Institutes of Health -
AC5 Inhibitor for Obesity
Amount: $133,845.00DESCRIPTION (provided by applicant): The goal of this proposal is to develop a drug that will be therapeutic for obesity and diabetes and improve exercise tolerance. Obesity, diabetes and exercise are ...
STTRPhase I2010Department of Health and Human Services National Institutes of Health -
Prevention of Cardiac Cell Death by Mst1 inhibitor
Amount: $1,107,190.00DESCRIPTION (provided by applicant): 6. Abstract Almost 20 million people suffer from ischemic heart diseases in US and one million patients develop myocardial infarction (MI) every year. Many patient ...
STTRPhase II2010Department of Health and Human Services National Institutes of Health -
Primate Model for Pharmaceutical Development
Amount: $393,566.00DESCRIPTION (provided by applicant): Advances in molecular medicine and genomic research promise to produce exciting new strategies for the treatment of human diseases. One significant concern regardi ...
STTRPhase II2007Department of Health and Human Services National Institutes of Health
